Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can you believe he actually is on the management team of a biotech pennystock?! It is VERY interesting that miss you also posts on that stock's forum!
penny stock dreams
The Iranian angle is interesting, as in why are so many involved in this company? Pourhassan, Kazempour, Lalezari, Arman, and probably some of the wealthy private investors. Why does an Iranian always seem to be the leader of this company?
Why would any company chose to partner with Cytodyn when the molecule patent expires in 2 months and companies can formulate around any existing CYDY patent?
That strategy is working wonderfully for CYDY management who wouldn't be able to continuing drawing outsized comp packages if not for it!
Yes they can start then, but to say that CYDY would be years ahead of them would be false. For example, if they decided to start pursuing the indication for inflammation they would have the resources to get ahead of cash poor CYDY who doesn't have the money to run clinical trials or even hire a CRO. Also, this is assuming any new entrant would not have experience with CCR5 inhibitors when generic Maraviroc has been available for a while now and they could have been using that for any existing research.
A whole lot of word salad! Any experienced IP attorney at a top law firm hired by a biotech would run circles around cipher Tyler Blok. The fact of the matter is the foundational molecule patent expires on June 1, 2024 (62 days away) and after that any company can easily design around any of Cytodyn's exisiting formulation patents.
Scott Kelly took a nice hiatus from his medical career where for a few years he smiled like a fool into the camera and said "back to you Nader" for which he was paid by the longs $3M a year in total comp, about 10x what he made as a doctor. Yes, his comp ultimately came from the longs buying up inflated cydy shares, a good chunk of which he dumped in May 2020 during the HIV BLA fiasco. Nader also dumped his shares during this time, and he is charged with insider trading for doing so. Interestingly, Kelly avoided having these same charges even though he was Nader's boss in name as Chairman Of the Board.
This has always been just an insider self-enrichment vehicle from the get, hence the hiring of an utterly unqualified twice convicted felon as CEO way back when. Why would a felon ever be hired by any legit company in the USA? It just doesn't happen....unless you need to use the felon's "work experience".
What about Cyrus's fluffy promises of all that would be achieved in 2023?! Is Cyrus still at CYDY or did he go to the new job or is he working at both places?
Will Nader "feel like a newbie" once he gets sent to (hopefully) Leavenworth or (most likely) Club Fed? He did serve prison time before but its been a while so maybe a newbie again?
About as credible as "research" that came out of Reckner's lab.
Not a mystery. Go through the SEC documents they put out when their preferred shareholders sell. Its all the mom and pop small business owners that fund each raise.
Go through the 10K and explain how the company survives past this year. Every capital raise has brought in less and less.
Once it loses the arbitration to Amarex it is lights out. Even if it somehow miraculously wins the arbitration, any money that comes in will be immediately claimed by creditors such as Samsung and the syringe vendor.
After this company goes bankrupt, when the tally is calculated of how much money was made not a single long would have made a fraction of what Pourhassan, Kelly, Mulholland made for spewing their bs during the big pump and dumps.
Any predicitons on the share price when the main patent expires on June 1, 2024? My guess is 0.09.
I always used to ask others why the heck is the CEO Pourhassan putting his name on scientific research papers when he contributed nothing to the research. That should have been a major red flag to the longs. Pourhassan was the classic narcissist who thought he could get away with anything. He never showed any remorse for his prior 2 felony convictions, apparently.
Didn't he actually say while CFO "don't worry about going concern warnings" or something to that effect? I would love to have a link to him saying that. I think it was on one of their investor presentation webcasts when they actually used to take live questions.
It is amazing he escaped the wrath of the SEC and DOJ. Esepcially after he said that Nasdaq uplisting was coming in 6 weeks back in early 2020 when he damn well knew that the company came nowhere near meeting exchange listing requirements. Do you think he is one of the un-named executives testifying against Nader and Kazem?
Nader and Scott dumped most of their shares in the $3.20 range. Even they never could imagine how wildly successful their pump turned out to be.
Speak in English and stop the "Sheik of Nodderspeak" act, if you get my drift. How's the weather in Spokane these days?
The main patent expires on June 1, 2024. This company had 20 years to commercialize the molecule and it could not. Those are the facts despite any spin coming out of Vancouver to the contrary.
A twice convicted Iranian felon laughed all the way to the bank with made up "82 %" numbers that the FDA specifically said was not statistically significant.
Those of you all about the molecule and "saving lives" could have potential new companies to invest in when the patent for the "Anti-CCR5 antibody" expires on June 1, 2024. Structure patents are the key. Function patents are easy to work around.
You are so right! We don't know he was in fact a crook, just like we don't know for a fact OJ killed Nicole and Ron! How astute you are!
Why'd they reward Dr. L with those 3M options that start vesting almost immediately? What did he do to earn that? Seems like he's just like old Nada with hot air announcements of what will be done instead of actually doing something.
Never said it was new. Just a well researched article that points out how these paid pr firms infiltrated message boards with fake credentialed aliases. Brings to mind a "doctor" that posts often on this board.
Here's a Seeking Alpha article that describes how another biotech pennystock hired promotional firms that posted on message boards under aliases with fictitious credentials (PhD, MD, hedge fund manager, etc) in an effort to pump up the stock price. The SEC used the research from this article. However, there has never been proof of paid "bashers" on message boards to drive down a share price to help shorts. That is fantasy.
Paid pumpers on forums
That is old news. The SEC and DOJ have been investigating Cytodyn and its former execs for close to 2 years now. This disclaimer is in every CYDY quarterly and annual SEC filing:
We have received subpoenas from the SEC and the U.S Department of Justice (the “DOJ”) requesting documents and information concerning, among other matters, leronlimab, our public statements regarding the use of leronlimab as a potential treatment for COVID19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, our retention of investor relations consultants, and trading in our securities. On December 20, 2022, the DOJ announced the unsealing of a criminal indictment charging both our former CEO, Nader Z. Pourhassan, and Kazem Kazempour, CEO of Amarex, our former CRO. That same day, the SEC announced charges against both Mr. Pourhassan and Mr. Kazempour for alleged violations of federal securities laws. The Company is cooperating fully with the DOJ and SEC investigations. We are unable to predict the effect of any governmental investigations on our business, financial condition, or reputation. In addition, publicity surrounding any investigation, even if ultimately resolved in our favor, could have a material adverse effect on our business
Another lawsuit, this one also naming Tanya. Those legal expenses must be piling up. Another round of dilution soon? Do they even have cash on hand to pay their lawyers since legit law firms don't want to be paid in junk OTC stock shares?
New lawsuit
Main patent expiring in less than 90 days, cash strapped, and any large influx of cash would immediately be claimed by Samsung in court. Sure does look like a buyout candidate!
What about the "condeeeshunal" EUA? LAUGHING
Anyone know the exact date the main patent on this mab from the 90's expires? I believe they started their HIV trials in 2004. 20 years is 2024.
They really miss the ole' felon Nadir. He could sell a nothing burger better than anyone they currently have. Too bad poor Nads is fighting for his very freedom right now. Maybe he can try to serve up Mike and Scott to the DOJ to cut a deal?
Hey Jonah! Leave them monkeys alone! Tick Tock on the main patent expiring in 90 some days.
Fife thanks the lolongs for providing him exit liquidity!
Was thinking about the Poppi Superbowl ad extolling the virtues of probiotic infused soda. Maybe Nadir can pitch leron infused soda from his cell? Full hold lifted yet?
Nader certainly had the cure for emptying these gullible longs pockets!
lol. How many otc penny stocks did Warren Buffet ever invest in?
Remember when Nadir employed 20 PR firms to pump this trash, some of whom were felons like himself? Good times.
From today's S1: We have written off the value of our pre-launch inventories of leronlimab and related raw materials, the costs of which were previously capitalized, and may be unable to use all or a portion of those inventories in the development of our product candidate.
Good luck finding another manufacturer after stiffing Samsung! This company will never run a clinical trial on humans again since it has no money to manufacture the drug. Unlike monkeys and rats, you can't inject humans with expired drugs.
Says who? By Cytodyn? Every person on its scientific board has been touted by them and pumpers as leaders and visionaries. What are the results the last 10 years? Looking at his CV he looks like just a run of the mill academic.